SymBiosis Capital takes 6.5% passive stake in Rani Therapeutics (RANI) Class A

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. disclosed that SymBiosis Capital Partners, LLC has filed a Schedule 13G reporting a significant passive stake in the company’s Class A Common Stock. SymBiosis reports beneficial ownership of 6,300,000 shares, representing 6.5% of the class, as of an event date of 11/13/2025.

SymBiosis has sole voting and sole dispositive power over all 6,300,000 shares, with no shared voting or dispositive authority. The filing is made on a passive basis, with SymBiosis certifying that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Rani Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Rani Therapeutics Holdings, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

0753018100

(CUSIP Number)

11/13/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 0753018100

1

Names of Reporting Persons

SymBiosis Capital Partners, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,300,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,300,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,300,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Rani Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 2051 RINGWOOD AVENUE, SAN JOSE, CALIFORNIA, 95131.
Item 2.
(a)	Name of person filing: SymBiosis Capital Partners, LLC
(b)	Address or principal business office or, if none, residence: 609 SW 8TH STREET, SUITE 510 BENTONVILLE, AR 72712
(c)	Citizenship: Delaware
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP No.: 0753018100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,300,000
(b)	Percent of class: 6.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6,300,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6,300,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SymBiosis Capital Partners, LLC

Signature:	/s/ Chidozie Ugwumba
Name/Title:	Managing Partner
Date:	02/12/2026

FAQ

What stake does SymBiosis Capital Partners report in Rani Therapeutics (RANI)?

SymBiosis Capital Partners reports beneficial ownership of 6,300,000 shares of Rani Therapeutics Class A Common Stock. This represents 6.5% of the outstanding class, giving SymBiosis a notable but minority position in the company’s equity.

Is SymBiosis Capital Partners a passive investor in Rani Therapeutics (RANI)?

Yes. SymBiosis Capital Partners certifies that the Rani Therapeutics shares were acquired and are held in the ordinary course of business. It states they are not held for the purpose of changing or influencing control of the issuer, consistent with a passive Schedule 13G filing.

How much voting power does SymBiosis have in Rani Therapeutics (RANI)?

SymBiosis reports sole voting power over 6,300,000 shares of Rani Therapeutics Class A Common Stock and no shared voting power. It also has sole dispositive power over the same shares, indicating full control over how these particular shares are voted and disposed.

When did the reportable ownership event occur for Rani Therapeutics (RANI)?

The reported ownership position in Rani Therapeutics became reportable as of 11/13/2025. That date is identified as the event which requires filing of the Schedule 13G, tying the 6.5% beneficial ownership level to that specific point in time.

What type of securities does SymBiosis hold in Rani Therapeutics (RANI)?

SymBiosis holds Class A Common Stock of Rani Therapeutics Holdings, Inc. The Schedule 13G specifies this class and ties the 6,300,000 beneficially owned shares and 6.5% ownership percentage specifically to that class of the company’s equity.

Who signed the Schedule 13G related to Rani Therapeutics (RANI)?

The Schedule 13G was signed by Chidozie Ugwumba, identified as a Managing Partner of SymBiosis Capital Partners, LLC. The signature block certifies that, to the best of the signer’s knowledge and belief, the information in the statement is true, complete, and correct.